The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Functions of Paracrine PDGF Signaling in the Proangiogenic Tumor Stroma Revealed by Pharmacological Targeting
Open accessAbstract
BACKGROUND: Important support functions, including promotion of tumor growth, angiogenesis, and invasion, have been attributed to the different cell types populating the tumor stroma, i.e., endothelial cells, cancer-associated fibroblasts, pericytes, and infiltrating inflammatory cells. Fibroblasts have long been recognized inside carcinomas and are increasingly implicated as functional participants. The stroma is prominent in cervical carcinoma, and distinguishable from nonmalignant tissue, suggestive of altered (tumor-promoting) functions. We postulated that pharmacological targeting of putative stromal support functions, in particular those of cancer-associated fibroblasts, could have therapeutic utility, and sought to assess the possibility in a pre-clinical setting. METHODS AND FINDINGS: We used a genetically engineered mouse model of cervical carcinogenesis to investigate platelet-derived growth factor (PDGF) receptor signaling in cancer-associated fibroblasts and pericytes. Pharmacological blockade of PDGF receptor signaling with the clinically approved kinase inhibitor imatinib slowed progression of premalignant cervical lesions in this model, and impaired the growth of preexisting invasive carcinomas. Inhibition of stromal PDGF receptors reduced proliferation and angiogenesis in cervical lesions through a mechanism involving suppression of expression of the angiogenic factor fibroblast growth factor 2 (FGF-2) and the epithelial cell growth factor FGF-7 by cancer-associated fibroblasts. Treatment with neutralizing antibodies to the PDGF receptors recapitulated these effects. A ligand trap for the FGFs impaired the angiogenic phenotype similarly to imatinib. Thus PDGF ligands expressed by cancerous epithelia evidently stimulate PDGFR-expressing stroma to up-regulate FGFs, promoting angiogenesis and epithelial proliferation, elements of a multicellular signaling network that elicits functional capabilities in the tumor microenvironment. CONCLUSIONS: This study illustrates the therapeutic benefits in a mouse model of human cervical cancer of mechanism-based targeting of the stroma, in particular cancer-associated fibroblasts. Drugs aimed at stromal fibroblast signals and effector functions may prove complementary to conventional treatments targeting the overt cancer cells for a range of solid tumors, possibly including cervical carcinoma, the second most common lethal malignancy in women worldwide, for which management remains poor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Self-citationNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“, dasatinib) might prove beneficial when combined with VEGF receptor inhibitors and/or with chemotherapy in more flexible combinations than strictly simultaneous dosing, involving evolutions of the chemo-switch regimen [36]; thus we might imagine first normalizing the tumor vasculature with VEGF pathway inhibitors [65…”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor
Heldin, C.-H., & Westermark, B. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1283 · Cited by 2,496
Stromal fibroblasts in cancer initiation and progression
Bhowmick, N. A., Neilson, E. G., & Moses, H. L. (2004) · Nature · doi:10.1038/nature03096 · Cited by 2,302
Genes Expressed in Human Tumor Endothelium
Croix, B. S., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., et al. (2000) · Science · doi:10.1126/science.289.5482.1197 · Cited by 1,845
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Self-citationTGF-ß Signaling in Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia
Bhowmick, N. A., Chytil, A., Plieth, D., Gorska, A. E., Dumont, N., Shappell, S., Washington, M. K., Neilson, E. G., & Moses, H. L. (2004) · Science · doi:10.1126/science.1090922 · Cited by 1,401
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,370
Self-citationMolecular characterization of the tumor microenvironment in breast cancer
Allinen, M., Beroukhim, R., Cai, L., Brennan, C., Lahti-Domenici, J., Huang, H., Porter, D., Hu, M., Chin, L., Richardson, A., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.010 · Cited by 1,299
Endothelial-pericyte interactions in angiogenesis
Gerhardt, H., & Betsholtz, C. (2003) · Cell and Tissue Research · doi:10.1007/s00441-003-0745-x · Cited by 1,057
Role of tissue stroma in cancer cell invasion
De Wever, O., & Mareel, M. (2003) · The Journal of Pathology · doi:10.1002/path.1398 · Cited by 1,042 · cited 1×
“]. In addition to the endothelial cells forming the tumor vasculature, attention is now focused on other elements of the stromal compartment, i.e. carcinoma-associated fibroblasts (CAFs), vascular pericytes, and infiltrating inflammatory cells. These cell types are being implicated as functionally important for tumori…”
BackgroundTumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Giraudo, E., Inoue, M., & Hanahan, D. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200422087 · Cited by 700
Self-citationHost cyclooxygenase-2 modulates carcinoma growth
Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., & DuBois, R. N. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9621 · Cited by 673
PDGF-C is a new protease-activated ligand for the PDGF α-receptor
Li, X., Pontén, A., Aase, K., Karlsson, L., Abramsson, A., Uutela, M., Bäckström, G., Hellström, M., Boström, H., Li, H., et al. (2000) · Nature Cell Biology · doi:10.1038/35010579 · Cited by 623
Erber, R., Thurnher, A., D. Katsen, A., Groth, G., Kerger, H., Hammes, H., D. Menger, M., Ullrich, A., & Vajkoczy, P. (2004) · The FASEB Journal · doi:10.1096/fj.03-0271fje · Cited by 610
Therapeutic targeting of the tumor microenvironment
Joyce, J. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.024 · Cited by 582
Song, S., Ewald, A. J., Stallcup, W., Werb, Z., & Bergers, G. (2005) · Nature Cell Biology · doi:10.1038/ncb1288 · Cited by 548
Self-citationPietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Self-citationPDGF receptors as cancer drug targets
Pietras, K., Sjöblom, T., Rubin, K., Heldin, C.-H., & Östman, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00089-8 · Cited by 465
Self-citationInhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
Pietras, K., Rubin, K., Sjöblom, T., Buchdunger, E., Sjöquist, M., Heldin, C., & Östman, A. (2002) · PubMed · Cited by 433
Self-citationKnow thy neighbor: stromal cells can contribute oncogenic signals
Tlsty, T. D., & Hein, P. W. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00156-8 · Cited by 425
Moinfar, F., Man, Y., Arnould, L., Bratthauer, G. L., Ratschek, M., & Tavassoli, F. A. (2000) · PubMed · Cited by 403
The influence of the microenvironment on the malignant phenotype
Park, C. C., Bissell, M. J., & Barcellos-Hoff, M. H. (2000) · Molecular Medicine Today · doi:10.1016/s1357-4310(00)01756-1 · Cited by 398
Riley, R. R., Duensing, S. M., Brake, T., Münger, K., Lambert, P. F., & Arbeit, J. M. (2003) · PubMed · Cited by 342
Host Prostaglandin E2-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth
Amano, H., Hayashi, I., Endo, H., Kitasato, H., Yamashina, S., Maruyama, T., Kobayashi, M., Satoh, K., Narita, M., Sugimoto, Y., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021408 · Cited by 325
Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice
Arbeit, J. M., Münger, K., Howley, P. M., & Hanahan, D. (1994) · Journal of Virology · doi:10.1128/jvi.68.7.4358-4368.1994 · Cited by 305
Self-citationArbeit, J. M., Howley, P. M., & Hanahan, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2930 · Cited by 304
Self-citationVEGF‐null cells require PDGFR α signaling‐mediated stromal fibroblast recruitment for tumorigenesis
Dong, J., Grunstein, J., Tejada, M., Peale, F., Frantz, G., Liang, W., Bai, W., Yu, L., Kowalski, J., Liang, X., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600289 · Cited by 295
Uehara, H., Kim, S. J., Karashima, T., Shepherd, D. L., Fan, D., Tsan, R., Killion, J. J., Logothetis, C., Mathew, P., & Fidler, I. J. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.458 · Cited by 280
Fibroblast growth factors are required for efficient tumor angiogenesis.
Compagni, A., Wilgenbus, P., Impagnatiello, M.-A., Cotten, M. L., & Christofori, G. (2000) · PubMed · Cited by 258
PDGF alpha- and beta-receptors activate unique and common signal transduction pathways.
Eriksson, A., Siegbahn, A., Westermark, B., Heldin, C. H., & Claesson-Welsh, L. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05085.x · Cited by 256
Forsberg, K., Valyi-Nagy, I., Heldin, C. H., Herlyn, M., & Westermark, B. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.393 · Cited by 238
Tumorigenic conversion of immortal human keratinocytes through stromal cell activation
Skobe, M., & Fusenig, N. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1050 · Cited by 233
Human breast carcinoma desmoplasia is PDGF initiated
Shao, Z.-M., Nguyen, M., & Barsky, S. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203785 · Cited by 221
Furuhashi, M., Sjöblom, T., Abramsson, A., Ellingsen, J., Micke, P., Li, H., Bergsten-Folestad, E., Eriksson, U., Heuchel, R., Betsholtz, C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1489 · Cited by 203
Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis.
Elson, D. A., Riley, R. R., Lacey, A., Thórdarson, G., Talamantes, F. J., & Arbeit, J. M. (2000) · PubMed · Cited by 187
Sano, H., Sudo, T., Yokode, M., Murayama, T., Kataoka, H., Takakura, N., Nishikawa, S., Nishikawa, S.-I., & Kita, T. (2001) · Circulation · doi:10.1161/01.cir.103.24.2955 · Cited by 169
Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy
Micke, P., & Östman, A. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.6.1217 · Cited by 162
Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors.
Inoue, M., Kyo, S., Fujita, M., Enomoto, T., & Kondoh, G. (1994) · PubMed · Cited by 159
Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics
R BOARD, & Jayson, G. C. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.03.004 · Cited by 157
Tejada, M. L., Yu, L., Dong, J., Jung, K., Meng, G., Peale, F. V., Jr., Frantz, G. D., Hall, L., Liang, X., Gerber, H., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1770 · Cited by 148
Smith‐McCune, K., Zhu, Y. H., Hanahan, D., & Arbeit, J. M. (1997) · PubMed · Cited by 127
Self-citationGius, D. R., Funk, M. C., Chuang, E. Y.-Y., Feng, S., Huettner, P. C., Nguyen, L., Bradbury, C. M., Mishra, M. V., Gao, S., Buttin, B. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0260 · Cited by 105
Expression in lung carcinomas of platelet-derived growth factor and its receptors.
Kawai, T., Hiroi, S., & Torikata, C. (1997) · PubMed · Cited by 97
Angiogenesis gene expression profiling in xenograft models to study cellular interactions
Thijssen, V. L., Brandwijk, R. J. M. G. E., Dings, R. P. M., & Griffioen, A. W. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.06.014 · Cited by 91
Smith, K., Fox, S. B., Whitehouse, R., Taylor, M., Greenall, M. J., Clarke, J., & Harris, A. L. (1999) · Annals of Oncology · doi:10.1023/a:1008303614441 · Cited by 90
Ikeda, Y., Hayashi, I., Kamoshita, E., Yamazaki, A., Endo, H., Ishihara, K., Yamashina, S., Tsutsumi, Y., Matsubara, H., & Majima, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3589 · Cited by 89
Lindmark, G. E., Sundberg, C., Glimelius, B. L. G., et al. (1993) · PubMed · Cited by 82
Bhardwaj, B., Klassen, J., Cossette, N., et al. (1996) · PubMed · Cited by 81
Sundberg, C., Branting, M., Gerdin, B., & Rubin, K. (1997) · Europe PMC (PubMed Central) · Cited by 73
Trappen, P. O. V., Ryan, A., Carroll, M., Lecœur, C., Goff, L. K., Gyselman, V. G., Young, B. D., Lowe, D. G., Pepper, M. S., Shepherd, J. H., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600471 · Cited by 72
Mapping the Human Proteome Using Antibodies
Uhlén, M. (2007) · Molecular & Cellular Proteomics · doi:10.1016/s1535-9476(20)32163-0 · Cited by 56
Castle, P. E. (2004) · Journal of Lower Genital Tract Disease · doi:10.1097/00128360-200407000-00011 · Cited by 45
Expression of basic fibroblast growth factor and its mRNA in advanced uterine cervical cancers
Fujimoto, J., Ichigo, S., Hori, M., Hirose, R., Sakaguchi, H., & Tamaya, T. (1997) · Cancer Letters · doi:10.1016/s0304-3835(96)04485-0 · Cited by 38
Cited by
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Self-citationThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Modes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
Self-citationRole of platelet-derived growth factors in physiology and medicine
Andrae, J., Gallini, R., & Betsholtz, C. (2008) · Genes & Development · doi:10.1101/gad.1653708 · Cited by 2,438
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Metadata
- Authors
- Pietras, K., Pahler, J., Bergers, G., & Hanahan, D.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-01-29
- Volume
- 5
- Issue
- 1
- Pages
- e19
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2063249586
- Cited by
- 453
- References
- 57
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.